Market Cap 48.39B
Revenue (ttm) 21.84B
Net Income (ttm) 1.68B
EPS (ttm) N/A
PE Ratio 12.53
Forward PE 13.89
Profit Margin 7.68%
Debt to Equity Ratio 0.67
Volume 2,651,200
Avg Vol 2,668,833
Day's Range N/A - N/A
Shares Out 284.74M
Stochastic %K 11%
Beta 0.24
Analysts Sell
Price Target $194.08

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 201 847 6800
Website: www.bd.com
Address:
1 Becton Drive, Franklin Lakes, United States
ZacksResearch
ZacksResearch Mar. 6 at 6:47 PM
$BDX shares have plunged 11.3% over the past six months despite new CE Mark approval for Revello stent — are investors missing the potential? 🤔 🔍 CE Mark strengthens BD’s footing in the growing PAD market 📈 Expanding minimally invasive vascular solutions could boost long-term growth in a market projected to grow at a CAGR of 7.56% Opportunity assessment here 👉 https://www.zacks.com/stock/news/2880337/bdx-secures-ce-mark-for-revello-stent-to-treat-iliac-artery-disease?cid=sm-stocktwits-2-2880337-body-36467&ADID=SYND_STOCKTWITS_TWEET_2_2880337_BODY_36467
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 5:47 PM
$BDX just scored a key regulatory win in vascular treatment. The company secured CE Mark for its Revello vascular covered stent designed to treat iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market. 🩺 See why this development matters for the stock 👉 https://www.zacks.com/stock/news/2880337/bdx-secures-ce-mark-for-revello-stent-to-treat-iliac-artery-disease?cid=sm-stocktwits-2-2880337-teaser-36407&ADID=SYND_STOCKTWITS_TWEET_2_2880337_TEASER_36407
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 6:53 PM
$BDX just secured a new FDA clearance — expanding its surgical toolkit. The company received FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system, adding a powered lavage option to its surgical irrigation portfolio. 🏥 See what this approval could mean for the business 👉 https://www.zacks.com/stock/news/2879660/bd-gains-fda-clearance-for-surgiphor-1000ml-surgical-irrigation-system?cid=sm-stocktwits-2-2879660-teaser-36241&ADID=SYND_STOCKTWITS_TWEET_2_2879660_TEASER_36241
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 5:53 PM
$BDX gets FDA clearance for Surgiphor 1000mL — but shares have lost 1.6% since Monday! 🤔 The new antimicrobial irrigation system aims to enhance surgical efficiency and patient care, yet shares have slid 10.9% over the past six months, underperforming its industry and the S&P 500. Discover the potential long-term impact for BDX 👉 https://www.zacks.com/stock/news/2879660/bd-gains-fda-clearance-for-surgiphor-1000ml-surgical-irrigation-system?cid=sm-stocktwits-2-2879660-body-36229&ADID=SYND_STOCKTWITS_TWEET_2_2879660_BODY_36229
0 · Reply
StockNews_Live
StockNews_Live Mar. 2 at 11:50 AM
$BDX BD (Becton, Dickinson and Company) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Surgiphor™ 1000mL, a 1000 mL antimicrobial irrigation system specific…
0 · Reply
11thestate
11thestate Feb. 26 at 2:59 PM
$BDX investors, if you follow us, you already know about it. This info hits different after the news. Check it out: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 6:04 PM
$BDX just upgraded a routine test — and it’s smarter than it sounds. 🧪 The new three-tube Urine Complete Cup Kit expands testing from a single sample, aiming to boost lab efficiency and reduce contamination risks. That’s workflow improvement + accuracy in one move. Incremental innovation… or a quiet margin lever? See what this could mean for the bigger picture 👉 https://www.zacks.com/stock/news/2874553/bd-launches-urine-complete-cup-kit-for-smarter-testing-accuracy?cid=sm-stocktwits-2-2874553-teaser-34977&ADID=SYND_STOCKTWITS_TWEET_2_2874553_TEASER_34977
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 5:04 PM
$BDX launches innovative urine collection kit — but shares dip. What’s up? 🤔 Despite launching the BD Vacutainer Urine Complete Cup Kit to enhance diagnostic testing and improve lab efficiency, BDX shares fell 0.6% yesterday. Over the past six months, the stock has declined 5.3%, underperforming the industry’s 22.3% growth. Currently, BDX holds a Zacks Rank #5 (Strong Sell). Discover the full story and potential implications here 👉 https://www.zacks.com/stock/news/2874553/bd-launches-urine-complete-cup-kit-for-smarter-testing-accuracy?cid=sm-stocktwits-2-2874553-body-34942&ADID=SYND_STOCKTWITS_TWEET_2_2874553_BODY_34942
0 · Reply
11thestate
11thestate Feb. 17 at 1:46 PM
$BDX has agreed to settle with investors over claims that it misled them about the functionality, safety, and regulatory status of its Alaris infusion pump system. Who’s eligible? Anyone who purchased $BDX shares between November 5, 2019 and February 5, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $2.14 — but normally only ~25% of eligible investors file, the effective payout could increase to $8.56. Can I still file? Yes — late claims are currently being considered for compensation, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Feb. 11 at 7:01 PM
$BDX just reshaped its future — and walked away with $4B in the process. 💰 The company completed its Biosciences & Diagnostic spin-off and merger with Waters, locking in $4B in proceeds as it pivots to a pure-play MedTech focus. That’s a major strategic reset. See what this transformation means for shareholders 👉 https://www.zacks.com/stock/news/2855593/bd-merges-biosciences-diagnostics-business-with-waters?cid=sm-stocktwits-2-2855593-teaser-33195&ADID=SYND_STOCKTWITS_TWEET_2_2855593_TEASER_33195
0 · Reply
Latest News on BDX
Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 7 days ago

Best Dividend Aristocrats For March 2026

ABBV ABT ADM ADP AFL ALB AMCR


Lanesha Minnix Named General Counsel for BD

Feb 19, 2026, 4:15 PM EST - 15 days ago

Lanesha Minnix Named General Counsel for BD


What's Going On With Becton Dickinson Stock Tuesday?

Feb 10, 2026, 2:17 PM EST - 24 days ago

What's Going On With Becton Dickinson Stock Tuesday?


Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings

Feb 9, 2026, 10:01 AM EST - 25 days ago

Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings


BD Reports First Quarter Fiscal 2026 Financial Results

Feb 9, 2026, 6:30 AM EST - 25 days ago

BD Reports First Quarter Fiscal 2026 Financial Results


Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 5 weeks ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BKH


MoneyShow's Best Investment Ideas For 2026: Part 2

Jan 12, 2026, 4:20 PM EST - 7 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 2

AXSM BRO BX CALM


BD To Host Virtual 2026 Annual Meeting of Shareholders

Jan 12, 2026, 4:15 PM EST - 7 weeks ago

BD To Host Virtual 2026 Annual Meeting of Shareholders


Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 2 months ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR


Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 2 months ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BKH


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 3 months ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


ZacksResearch
ZacksResearch Mar. 6 at 6:47 PM
$BDX shares have plunged 11.3% over the past six months despite new CE Mark approval for Revello stent — are investors missing the potential? 🤔 🔍 CE Mark strengthens BD’s footing in the growing PAD market 📈 Expanding minimally invasive vascular solutions could boost long-term growth in a market projected to grow at a CAGR of 7.56% Opportunity assessment here 👉 https://www.zacks.com/stock/news/2880337/bdx-secures-ce-mark-for-revello-stent-to-treat-iliac-artery-disease?cid=sm-stocktwits-2-2880337-body-36467&ADID=SYND_STOCKTWITS_TWEET_2_2880337_BODY_36467
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 5:47 PM
$BDX just scored a key regulatory win in vascular treatment. The company secured CE Mark for its Revello vascular covered stent designed to treat iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market. 🩺 See why this development matters for the stock 👉 https://www.zacks.com/stock/news/2880337/bdx-secures-ce-mark-for-revello-stent-to-treat-iliac-artery-disease?cid=sm-stocktwits-2-2880337-teaser-36407&ADID=SYND_STOCKTWITS_TWEET_2_2880337_TEASER_36407
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 6:53 PM
$BDX just secured a new FDA clearance — expanding its surgical toolkit. The company received FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system, adding a powered lavage option to its surgical irrigation portfolio. 🏥 See what this approval could mean for the business 👉 https://www.zacks.com/stock/news/2879660/bd-gains-fda-clearance-for-surgiphor-1000ml-surgical-irrigation-system?cid=sm-stocktwits-2-2879660-teaser-36241&ADID=SYND_STOCKTWITS_TWEET_2_2879660_TEASER_36241
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 5:53 PM
$BDX gets FDA clearance for Surgiphor 1000mL — but shares have lost 1.6% since Monday! 🤔 The new antimicrobial irrigation system aims to enhance surgical efficiency and patient care, yet shares have slid 10.9% over the past six months, underperforming its industry and the S&P 500. Discover the potential long-term impact for BDX 👉 https://www.zacks.com/stock/news/2879660/bd-gains-fda-clearance-for-surgiphor-1000ml-surgical-irrigation-system?cid=sm-stocktwits-2-2879660-body-36229&ADID=SYND_STOCKTWITS_TWEET_2_2879660_BODY_36229
0 · Reply
StockNews_Live
StockNews_Live Mar. 2 at 11:50 AM
$BDX BD (Becton, Dickinson and Company) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Surgiphor™ 1000mL, a 1000 mL antimicrobial irrigation system specific…
0 · Reply
11thestate
11thestate Feb. 26 at 2:59 PM
$BDX investors, if you follow us, you already know about it. This info hits different after the news. Check it out: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 6:04 PM
$BDX just upgraded a routine test — and it’s smarter than it sounds. 🧪 The new three-tube Urine Complete Cup Kit expands testing from a single sample, aiming to boost lab efficiency and reduce contamination risks. That’s workflow improvement + accuracy in one move. Incremental innovation… or a quiet margin lever? See what this could mean for the bigger picture 👉 https://www.zacks.com/stock/news/2874553/bd-launches-urine-complete-cup-kit-for-smarter-testing-accuracy?cid=sm-stocktwits-2-2874553-teaser-34977&ADID=SYND_STOCKTWITS_TWEET_2_2874553_TEASER_34977
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 5:04 PM
$BDX launches innovative urine collection kit — but shares dip. What’s up? 🤔 Despite launching the BD Vacutainer Urine Complete Cup Kit to enhance diagnostic testing and improve lab efficiency, BDX shares fell 0.6% yesterday. Over the past six months, the stock has declined 5.3%, underperforming the industry’s 22.3% growth. Currently, BDX holds a Zacks Rank #5 (Strong Sell). Discover the full story and potential implications here 👉 https://www.zacks.com/stock/news/2874553/bd-launches-urine-complete-cup-kit-for-smarter-testing-accuracy?cid=sm-stocktwits-2-2874553-body-34942&ADID=SYND_STOCKTWITS_TWEET_2_2874553_BODY_34942
0 · Reply
11thestate
11thestate Feb. 17 at 1:46 PM
$BDX has agreed to settle with investors over claims that it misled them about the functionality, safety, and regulatory status of its Alaris infusion pump system. Who’s eligible? Anyone who purchased $BDX shares between November 5, 2019 and February 5, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $2.14 — but normally only ~25% of eligible investors file, the effective payout could increase to $8.56. Can I still file? Yes — late claims are currently being considered for compensation, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Feb. 11 at 7:01 PM
$BDX just reshaped its future — and walked away with $4B in the process. 💰 The company completed its Biosciences & Diagnostic spin-off and merger with Waters, locking in $4B in proceeds as it pivots to a pure-play MedTech focus. That’s a major strategic reset. See what this transformation means for shareholders 👉 https://www.zacks.com/stock/news/2855593/bd-merges-biosciences-diagnostics-business-with-waters?cid=sm-stocktwits-2-2855593-teaser-33195&ADID=SYND_STOCKTWITS_TWEET_2_2855593_TEASER_33195
0 · Reply
ZacksResearch
ZacksResearch Feb. 11 at 6:01 PM
$BDX completes strategic spin-off — what's next for the MedTech giant? 🤔 🔄 BD spins off Biosciences & Diagnostic, merging it with Waters, and receives $4B cash for strategic use. 📉 Shares have fallen 17.2% since the announcement. 📊 BD aims to leverage AI, connected medical tech, and chronic disease solutions for growth. Discover the full strategic impact here 👉 https://www.zacks.com/stock/news/2855593/bd-merges-biosciences-diagnostics-business-with-waters?cid=sm-stocktwits-2-2855593-body-33178&ADID=SYND_STOCKTWITS_TWEET_2_2855593_BODY_33178
0 · Reply
Okadarlan
Okadarlan Feb. 10 at 8:22 PM
$BDX The chart looks so different then it does on the exchange, i would still wait for a lower price, 150s and then we take a starter, thats the decade low.
0 · Reply
sherowcap
sherowcap Feb. 10 at 8:13 PM
$BDX Finally a good day for long-term holders and the $WAT shares I will definitely keep, add to over next week. BDX will now be buying back 4% of the Co in an ASR over the next few months and trades 13.5x a conservative guide for this year. Headed up ⬆️
0 · Reply
bluffmeariver
bluffmeariver Feb. 10 at 4:55 PM
$BDX Crazy s*** if you bought from February 5th to yesterday You DONT get SPIN OFF But your price tanks 15% BULLSHIT $LLYX.X $SRPT $ABT
0 · Reply
bluffmeariver
bluffmeariver Feb. 10 at 4:00 PM
$BDX why drop 15% today? If we bougt yesterday do we have right for a spin-off?
0 · Reply
PickAlpha
PickAlpha Feb. 10 at 1:00 PM
PickAlpha Morning Report | 2026-02-10 — 7 material moves and analysis • WTI and RBOB rise 1 3 supply risk eased — $XLE, $SPY • Becton Dickinson gets 4B from spin merger — $BDX, $WAT • NY Fed inflation expectations fall to 3 10 — $SPY, $DX-Y.NYB • Etc.. https://research.pickalpha.ai/p/pickalpha-morning-report-2026-02-011
0 · Reply
PickAlpha
PickAlpha Feb. 10 at 12:56 PM
PickAlpha Morning Report - Company News: 2026.02.10 News Analysis - 1/5: Becton Dickinson completes spin-off and merger of Biosciences & Diagnostics unit with Waters, receives $4BN cash for buybacks and debt paydown | View: The transaction is closed and capital allocation plans are defined… $BDX $WAT $XLV $SPY
0 · Reply
bluffmeariver
bluffmeariver Feb. 10 at 10:27 AM
$BDX why 15% drop today. Spinoff ex day was a week ago $ABT $LLYX.X $SRPT
3 · Reply
Estimize
Estimize Feb. 10 at 1:51 AM
$BDX reported 2.91 EPS and 5,252 revenue for Q1. http://www.estimize.com/intro/bdx?chart=historical&metric_name=eps&utm_content=BDX&utm_med
0 · Reply
ZacksResearch
ZacksResearch Feb. 9 at 3:51 PM
$BDX beats EPS estimates, but shares dip 3.9% pre-market! 📉 Quarterly EPS of $2.91 topped the Zacks Consensus Estimate by 3.4%. Discover the full breakdown 👉 https://www.zacks.com/stock/news/2841608/bd-stock-dips-in-pre-market-despite-q1-earnings-beat-margins-up?cid=sm-stocktwits-2-2841608-body-32576&ADID=SYND_STOCKTWITS_TWEET_2_2841608_BODY_32576
0 · Reply
ZacksResearch
ZacksResearch Feb. 9 at 2:51 PM
$BDX beats Q1 earnings — yet the stock is dipping pre-market. 🤔📉 First-quarter fiscal 2026 delivered an earnings beat with revenue growth and expanding margins, but adjusted profit declined year over year, giving traders mixed signals. Dig into the full setup and what the market is reacting to 👉 https://www.zacks.com/stock/news/2841608/bd-stock-dips-in-pre-market-despite-q1-earnings-beat-margins-up?cid=sm-stocktwits-2-2841608-teaser-32564&ADID=SYND_STOCKTWITS_TWEET_2_2841608_TEASER_32564
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 9 at 1:44 PM
$BDX (-3.4% pre) BD stock slips despite Q1 FY26 beat https://ooc.bz/l/92502
0 · Reply